Last reviewed · How we verify
UC-MSC
UC-MSC is an umbilical cord-derived mesenchymal stem cell therapy that promotes tissue regeneration and modulates immune responses through paracrine signaling.
UC-MSC is an umbilical cord-derived mesenchymal stem cell therapy that promotes tissue regeneration and modulates immune responses through paracrine signaling. Used for Ulcerative colitis (phase 3).
At a glance
| Generic name | UC-MSC |
|---|---|
| Also known as | Umbilical Cord- Mesenchymal Stem Cell (UC-MSC), Human umbilical cord mesenchymal stem cells, Umbilical cord-derived mesenchymal stem cells, Transplantation Group |
| Sponsor | PT. Prodia Stem Cell Indonesia |
| Drug class | Cell therapy; mesenchymal stem cell product |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine; Immunology |
| Phase | Phase 3 |
Mechanism of action
Umbilical cord mesenchymal stem cells (UC-MSC) exert therapeutic effects by secreting bioactive factors including cytokines, growth factors, and extracellular vesicles that reduce inflammation, promote angiogenesis, and support tissue repair. These cells can differentiate into multiple cell types and create an immunomodulatory microenvironment that suppresses pathogenic immune responses while supporting regenerative processes.
Approved indications
- Ulcerative colitis (phase 3)
Common side effects
- Infusion-related reactions
- Infection
- Fever
Key clinical trials
- To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS). (PHASE3)
- Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment (PHASE1)
- Allogeneic Human Mesenchymal Stem Cell Infusion for Frailty Patient (NA)
- Pilot Study of Radiation-Induced Xerostomia Treatment With Allogeneic Mesenchymal Stromal Stem Cells (PHASE1)
- Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis (PHASE1, PHASE2)
- Stem Cell and Conditioned Medium for Cerebral Palsy (PHASE1, PHASE2)
- Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis (PHASE1, PHASE2)
- Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UC-MSC CI brief — competitive landscape report
- UC-MSC updates RSS · CI watch RSS
- PT. Prodia Stem Cell Indonesia portfolio CI